Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wi...
Main Authors: | Qing ZHOU, Shun LU, Yong LI, Fujun JIA, Guanjun LI, Zhen HONG, You LU, Yun FAN, Jianying ZHOU, Zhe LIU, Juan LI, Yi-Long WU, Chinese Thoracic Oncology Group (CTONG), Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-08-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39 |
Similar Items
-
First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01) -
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
by: Shunsuke Teraoka, MD, et al.
Published: (2024-03-01) -
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01) -
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
by: Qing Zhou, MD, PhD, et al.
Published: (2023-05-01) -
Recent Advances in the Management of Adverse Events Associated with Lorlatinib
by: Liao D, et al.
Published: (2023-09-01)